NASDAQ:BFRI Biofrontera Q1 2026 Earnings Report $1.07 -0.04 (-3.60%) As of 11:43 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Biofrontera EPS ResultsActual EPSN/AConsensus EPS -$0.12Beat/MissN/AOne Year Ago EPSN/ABiofrontera Revenue ResultsActual RevenueN/AExpected Revenue$10.25 millionBeat/MissN/AYoY Revenue GrowthN/ABiofrontera Announcement DetailsQuarterQ1 2026Date5/21/2026TimeBefore Market OpensConference Call DateThursday, May 14, 2026Conference Call Time11:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Biofrontera Earnings HeadlinesBiofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026May 8, 2026 | markets.businessinsider.comReviewing Biofrontera (NASDAQ:BFRI) & Vertex Pharmaceuticals (NASDAQ:VRTX)May 7, 2026 | americanbankingnews.comPeptide Company Lands Exclusive MMA Wellness PartnershipA publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform tied to Conor McGregor and Dana White - reaching millions of combat sports and biohacking followers worldwide. On April 15, RFK Jr. announced the FDA would remove 12 peptides from restricted Category 2 status. This company was already selling products tied to three of those peptides - and has developed a patent-pending transdermal patch addressing the 63.2% of adults with needle phobia. The peptide therapeutics market is projected to reach $294 billion by 2033.May 12 at 1:00 AM | The Tomorrow Investor (Ad)Biofrontera Inc (BFRI) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...March 20, 2026 | finance.yahoo.comBiofrontera Inc. (NASDAQ:BFRI) Q4 2025 earnings call transcriptMarch 20, 2026 | msn.comBiofrontera Inc. (BFRI) Q4 2025 Earnings Call TranscriptMarch 19, 2026 | seekingalpha.comSee More Biofrontera Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Biofrontera? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biofrontera and other key companies, straight to your email. Email Address About BiofronteraBiofrontera (NASDAQ:BFRI) AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue. The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis. Ameluz is used in combination with the BF-RhodoLED® lamp, a medical device designed to emit the precise wavelength of red light required to activate the gel. This integrated pharmaceutical–device approach underpins the company’s position in the PDT market. Founded in 1997 and headquartered in Leverkusen, Germany, Biofrontera maintains operations in multiple geographies, including a U.S. subsidiary established to support commercialization efforts in North America. Beyond its approved indications, the company is exploring additional dermatological uses for its photodynamic platform and is engaged in discussions with regulatory authorities and commercial partners to expand its presence in key markets such as Canada, Turkey and beyond. Biofrontera’s management team brings together expertise in dermatology, pharmaceutical development and medical device manufacturing. The company continues to invest in its pipeline, seeking to leverage its PDT technology for new indications and to forge strategic partnerships that will broaden access to its therapies worldwide.View Biofrontera ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles On Holdings Sets Up for Marathon Rally: New Highs Are ComingMP Materials Is Quietly Building a Rare Earth PowerhouseUbiquiti’s Uptrend Can Continue, But Don’t Rush to Buy ItAI Demand Fuels Strong Q1 Earnings for Constellation EnergyMercadoLibre Boldly Invests in Growth: Discount DeepensManic Monday.com: The Rally Is Just the Beginning for this SaaS LeaderMeta Platforms’ Wild Post-Earnings Swings: Where Analyst Price Targets Stand Now Upcoming Earnings Cisco Systems (5/13/2026)Alibaba Group (5/13/2026)Manulife Financial (5/13/2026)Sumitomo Mitsui Financial Group (5/13/2026)Takeda Pharmaceutical (5/13/2026)Applied Materials (5/14/2026)Brookfield (5/14/2026)National Grid Transco (5/14/2026)NU (5/14/2026)Mizuho Financial Group (5/15/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
